Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 19;13(18):5543.
doi: 10.3390/jcm13185543.

Tricuspid Regurgitation Associated with Implantable Cardiac Devices: A Double-Edged Sword

Ștefan Iliescu  1 , Luminita Voroneanu  2   3 , Alexandra Maria Covic  1   2 , Dragos Viorel Scripcariu  4 , Cristian Stătescu  1   2 , Adrian C Covic  2   3
Affiliations
Review

Tricuspid Regurgitation Associated with Implantable Cardiac Devices: A Double-Edged Sword

Ștefan Iliescu et al. J Clin Med. .

Abstract

The use of cardiac implantable electronic devices (CIEDs) has increased considerably, becoming a cornerstone of management for patients with brady- or tachyarrhythmia or for the prevention of sudden cardiac death. On the other hand, tricuspid regurgitation (TR) associated with CIEDs is progressively accepted as a serious clinical issue; the prognostic impact of TR is profound, as it is independently associated with increased mortality and a higher risk of heart failure hospitalization. Additionally, the management of established CIED-related TR continues to be challenging, with limited options for intervention once significant TR has developed. The balance between the lifesaving benefits of CIEDs and the risk of TR underlines the necessity for cautious patient selection and innovative approaches to device implantation and management. This review highlights the clinical importance, underlying mechanisms and challenges associated with lead-related tricuspid regurgitation in patients with CIEDs.

Keywords: heart failure hospitalization; management; mortality; prognosis; tricuspid regurgitation after cardiac implantable devices.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Management options in lead-related tricuspid regurgitation.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mond H.G., Proclemer A. The 11th World Survey of Cardiac Pacing and Implantable Cardioverter-Defibrillators: Calendar Year 2009—A World Society of Arrhythmia’s Project. Pacing Clin. Electrophysiol. 2011;34:1013–1027. doi: 10.1111/j.1540-8159.2011.03150.x. - DOI - PubMed
    1. Andreas M., Burri H., Praz F., Soliman O., Badano L., Barreiro M., Cavalcante J.L., de Potter T., Doenst T., Friedrichs K., et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur. Heart J. 2024;45:346–365. doi: 10.1093/eurheartj/ehad783. - DOI - PMC - PubMed
    1. Chodór-Rozwadowska K., Sawicka M., Morawski S., Kalarus Z., Kukulski T. Tricuspid regurgitation (TR) after implantation of a cardiac implantable electronic device (CIED)-one-year observation of patients with or without left ventricular dysfunction. J. Cardiovasc. Dev. Dis. 2023;10:353. doi: 10.3390/jcdd10080353. - DOI - PMC - PubMed
    1. Vieitez J.M., Monteagudo J.M., Mahia P., Perez L., Lopez T., Marco I., Perone F., González T., Sitges M., Bouzas A., et al. New insights of tricuspid regurgitation: A large-scale prospective cohort study. Eur. Heart J. Cardiovasc. Imaging. 2021;22:196–202. doi: 10.1093/ehjci/jeaa205. - DOI - PubMed
    1. Gelves-Meza J., Lang R.M., Valderrama-Achury M.D., Zamorano J.L., Vargas-Acevedo C., Medina H.M., Salazar G. Tricuspid regurgitation related to cardiac implantable electronic devices: An integrative review. J. Am. Soc. Echocardiogr. 2022;35:1107–1122. doi: 10.1016/j.echo.2022.08.004. - DOI - PubMed

LinkOut - more resources